These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 34284438

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer.
    Zou Q, Jiao J, Zou MH, Li MZ, Yang T, Xu L, Zhang Y.
    Abdom Radiol (NY); 2020 Dec; 45(12):4202-4213. PubMed ID: 32948911
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Correlations between whole body volumetric parameters of 68Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients.
    Yildirim ÖA, Gündoğan C, Can C, Poyraz K, Erdur E, Kömek H.
    Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
    [Abstract] [Full Text] [Related]

  • 6. Predictive significance of intraprostatic volumetric parameters derived from early and standard time 68Ga-PSMA PET/CT images in newly diagnosed prostate cancer patients.
    Erdogan EB, Tekce E, Koca S, Aslan N, Toluk O, Aydin M.
    Nucl Med Commun; 2024 Jul 01; 45(7):629-641. PubMed ID: 38835183
    [Abstract] [Full Text] [Related]

  • 7. Semiautomatic assessment of whole-body tumor burden with 18F-PSMA-1007 in biochemical recurrent prostate cancer.
    Cardoza-Ochoa DR, Cristancho-Rojas C, Pérez DJ, Moreno-Izaguirre P, Guzman M, Gutiérrez-Rivera MC, Gaxiola-Mascareño AP, Avila-Rodríguez MA, Rivera-Bravo B.
    Nucl Med Commun; 2022 Mar 01; 43(3):332-339. PubMed ID: 34954764
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients.
    Aksu A, Karahan Şen NP, Tuna EB, Aslan G, Çapa Kaya G.
    Nucl Med Commun; 2021 May 01; 42(5):503-509. PubMed ID: 33560717
    [Abstract] [Full Text] [Related]

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 May 01; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of Gallium-68 prostate-specific membrane antigen, positron emission tomography/computed tomography (GA-68 PSMA PET/CT) in recurrent prostate cancer: a retrospective review of initial clinical experience at Tygerberg Hospital.
    Sangiwa BA, Burger C, Ellmann A.
    Pan Afr Med J; 2024 May 01; 48():30. PubMed ID: 39220559
    [Abstract] [Full Text] [Related]

  • 14. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?
    Karyağar S, Güven O, Karyağar SS, Arici S, Selvi O, Geredeli Ç, Özülker F.
    Nucl Med Commun; 2021 Sep 01; 42(9):1011-1016. PubMed ID: 33958536
    [Abstract] [Full Text] [Related]

  • 15. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
    Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2016 Jul 01; 43(7):1288-99. PubMed ID: 26753602
    [Abstract] [Full Text] [Related]

  • 16. The superior detection rate of total-body [68Ga]Ga-PSMA-11 PET/CT compared to short axial field-of-view [68Ga]Ga-PSMA-11 PET/CT for early recurrent prostate cancer patients with PSA < 0.2 ng/mL after radical prostatectomy.
    Wang Y, Dong L, Zhao H, Li L, Huang G, Xue W, Liu J, Chen R.
    Eur J Nucl Med Mol Imaging; 2024 Jul 01; 51(8):2484-2494. PubMed ID: 38514483
    [Abstract] [Full Text] [Related]

  • 17. Role of 68Ga-PSMA PET/CT parameters in treatment evaluation and survival prediction in prostate cancer patients compared with biochemical response assessment.
    Can C, Gündoğan C, Yildirim OA, Poyraz K, Güzel Y, Kömek H.
    Hell J Nucl Med; 2021 Jul 01; 24(1):25-35. PubMed ID: 33866336
    [Abstract] [Full Text] [Related]

  • 18. Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment.
    Telli TA, Ozguven S, Alan O, Filizoglu N, Ozturk MA, Sariyar N, Isik S, Arikan R, Demircan NC, Basoglu T, Cetin IA, Ones T, Ercelep O, Dane F, Yumuk PF.
    Ann Nucl Med; 2022 Nov 01; 36(11):964-975. PubMed ID: 35997890
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of whole-body tumor burden with 68Ga-PSMA PET/CT in the biochemical recurrence of prostate cancer.
    Brito AET, Mourato FA, de Oliveira RPM, Leal ALG, Filho PJA, de Filho JLL.
    Ann Nucl Med; 2019 May 01; 33(5):344-350. PubMed ID: 30746599
    [Abstract] [Full Text] [Related]

  • 20. Direct Patlak Reconstruction of [68Ga]Ga-PSMA PET for the Evaluation of Primary Prostate Cancer Prior Total Prostatectomy: Results of a Pilot Study.
    Rasul S, Geist BK, Einspieler H, Fajkovic H, Shariat SF, Schmitl S, Mitterhauser M, Bartosch R, Langsteger W, Baltzer PAT, Beyer T, Ferrara D, Haug AR, Hacker M, Rausch I.
    Int J Mol Sci; 2023 Sep 05; 24(18):. PubMed ID: 37761975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.